Cardiovascular complications of cancers and anti-cancer therapy

Česká verzia

Authors: Jiří Vyskočil ^1,2; Katarína Petráková ³; Petr Jelínek ¹; Michal Furdek ^1,2
Authors place of work: Oddělení anesteziologie a resuscitace/jednotka intenzivní péče MOÚ, Brno ¹; Interní ambulance MOÚ, Brno ²; Klinika komplexní onkologické péče LF MU a MOÚ, Brno ³
Published in the journal: Vnitř Lék 2017; 63(3): 200-209
Category: Reviews

Summary

In our aging population the incidence of cancer is increasing in the elderly. We are thus facing a new challenge especially considering incidence of cardiovascular diseases (CVD) in this patients’ population. Overall survival of cancer patients has significantly improved therefore cancer has become in many cases a chronic disease. We are about to be treating patients who either may develop a new CVD or their current CVD may deteriorate. Cancer can cause various cardiovascular conditions locally (pressure in mediastinum, effusions) or systemically (increased risk of pulmonary embolism, arrhythmias, carcinoid heart disease). Medical cancer therapy can lead to congestive heart failure (CHF) per se, by anthracycline or antiHER2 therapy direct cardiac toxicity or by number of other cardiac conditions medical treatment can cause, such as accelerated arterial hypertension due to anti-angiogenic therapy (tyrosine-kinase inhibitors, bevacizumab) or even standard chemotherapy (alkylating agents, cisplatin) or overusing steroids in cancer patients. Atrial fibrillation (AFib) also contributes to CHF development. AFib in cancer patients may develop secondary to ischaemia in anaemic patients, metabolic disorders caused by cancer or treatment, pulmonary embolism, sepsis or even as a result of direct impact of cytotoxic treatment (cisplatin, ifosfamide, gemcitabine, 5-fluorouracil, etoposide). One of major risk factors for CHF is coronary artery disease (CAD), which is a very serious late sequel of cancer therapy mainly in long time cancer survivors (testicular cancer, childhood cancer, hematologic malignancies, breast cancer). CAD may develop secondary to thoracic irradiation, dyslipidemia caused by hormonal treatment or simply as results of endothelial dysfunction caused by alkylating agents. In summary, long time cancer survivors represent a subgroup of patients at great risk of developing CVD in any form. It is crucial to mention that these patients can develop typical CVD much earlier compared to standard population and therefore require special follow-up with active surveillance.

Key words:
anthracycline – atrial fibrillation – cardiac toxicity – heart failure – pulmonary embolism

Zdroje

1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A. Lectures on clinical medicine delivered at the Hotel-Dieu, Paris. 5th ed. [translated by Cormack JR]. New Sydenham Society: London 1872: 281–295.

2. Fennerty A. Venous thromboembolic disease and cancer. Postgrad Med J 2006; 82(972): 642–648.

3. Bloom JW, Doggen CJM, Osanto S et al. Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 2005; 293(6): 715–722.

4. Kakkar AK, DeRuvo N, Chinswangwatanakul V et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346(8981): 1004–1005.

5. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6(6): 401–410.

6. Blom JW, Vanderschoot JP, Oostindier MJ et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4(3): 529–535.

7. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9(2): 286–294.

8. Rajkumar SV, Blood E, Vesole D et al. Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24(3): 431–436.

9. Keefe D, Bowen J, Gibson R et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011; 16(4): 432–444. Dostupné z DOI: <http://dx.doi.org/10.1634/theoncologist.2010–0271>.

10. Bennett LC, Silver SM, Djulbegovic B et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA 2008; 299(8): 914–924. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.299.8.914>.

11. Informace dostupné z WWW: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.

12. Mandala M, Falanga A, Roila F Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl 6): vi85-vi92. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdr392>.

13. Konstantinides SV, Torbicki A, Agnelli G et al. [Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)]. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35(43): 3033–3069, 3069a-3069k. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu283>.

14. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart 2004; 90(10): 1224–1228.

15. [Kooperativní skupina pro neuroendokrinní nádory]. Definice a historie NET. Dostupné z WWW: http://neuroendokrinni-nadory.cz/pro-odborniky. [13.12.2016].

16. Informace dostupné z WWW: <https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf>. [13/12/2016]

17. Palaniswamy C, Frishman WH, Aronow WS. Carcinoid heart disease. Cardiol Rev 2012; 20(4): 167–176. Dostupné z DOI: <http://dx.doi.org/10.1097/CRD.0b013e31824c866e>.

18. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291(20): 2441–2447.

19. Perez E, Morgan J. Cardiotoxicity of trastuzumab and other HER2-targeted agents. UpToDate. Dostupné z WWW: http://www.uptodate.com/contents/cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents.

20. de Jesus-Gonzalez N, Robinson E, Moslehi J et al. Management of antiangiogenic therapy-induced hypertension. Hypertension 2012; 60(3): 607–615. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.196774>.

21. Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J 2011; 38(3): 263–265.

22. Fraeman KH, Nordstrom BL, Luo W et al. Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study. Int J Hypertens 2013; 2013: 379252. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/379252>.

23. Ostenfeld EB, Erichsen R, Pedersen L et al. Atrial Fibrillation as a Marker of Occult Cancer. PLoS ONE 2014; 9(8): e102861. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0102861>.

24. Kirchhof P, Benussi S, Kotecha D et al. [Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association (EHRA) of the ESC. European Stroke Organisation (ESO)]. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18(11): 1609–1678. Dostupné z DOI: https://doi.org/10.1093/europace/euw295

25. Bovelli D, Plataniotis G, Roila F. ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy‐related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21(Suppl 5): v277-v282. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdq200>.

26. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014; 63(10): 945–953. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.11.026>.

27. Labianca R, Beretta G, Clerici M et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68(6): 505–510.

28. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced Cardiotoxicity. Mædica (Buchar) 2013; 8(1): 59–67.

29. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53(24): 2231–2247. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.02.050>.

30. Jaworski C, Mariani JA, Wheeler G et al. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61(23): 2319–2328. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.01.090>.

31. Boerma M, Kruse JJ, van Loenen M et al. Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol 2004; 180(2): 109–116.

32. Ng AK. Review of the Cardiac long-term effects of the therapy for Hodgkin lymphoma. Br J Heamatol 2011; 154(1): 23–31. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2011.08713.x>.

33. Hull MC, Morris CG, Pepine CJ et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290(21): 2831–2837.

34. Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368(11): 987–989. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1209825>.

35. van den Belt‐Dusebout AW, de Wit R, Gietema JA et al. Treatment‐specific risks of second malignancies and cardiovascular disease in 5‐year survivors of testicular cancer. J Clin Oncol 2007; 25(28): 4370–4378.

36. Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40(5): 701–706.

37. Zhoubný novotvar ovarií a tuby (C56–57). In: Modrá kniha. Česká onkologická společnost České lékařské společnosti Jana Evangelisty Purkyně. Dostupné z WWW: http://www.linkos.cz/informace-pro-praxi/modra-kniha/17-zhoubny-novotvar-ovarii-a-tuby-c56–57/ [13.12.2016].

38. Zhoubné novotvary lymfatických tkání (C81–86). In: Modrá kniha. Česká onkologická společnost České lékařské společnosti Jana Evangelisty Purkyně. Dostupné z WWW: http://www.linkos.cz/informace-pro-praxi/modra-kniha/26-zhoubne-novotvary-lymfatickych-tkani-c81–86/.[13.12.2016].

39. Dostupné z WWW: <https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf>. [13.12.2016].

40. Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23(16): 3718–3725.

41. Partridge AH, Gelber S, Peppercorn J et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer 2008; 8(1): 65–69. Dostupné z DOI: <http://dx.doi.org/10.3816/CBC.2008.n.004>.

42. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16(Suppl 2): S175-S181.

43. Foglietta J, Inno A, de Iuliis F et al. Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clin Breast Cancer. 2017; 17(1): 11–17. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clbc.2016.07.003>.

44. Van Hemelrijck M, Garmo H, Holmberg L et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 2010; 28(21): 3448–3456. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2010.29.1567>.

45. Poprach A, Petráková K, Vyskočil J et al. Kardiotoxicita léků používaných v onkologii. Klinická onkologie 2008; 21(5): 288–293.

46. Zeglinski M, Ludke A, Jassal DS et al. Trastuzumab-induced cardiac dysfunction: A “dual-hit.” Exp Clin Cardiol 2011 Fall; 16(3): 70–74.

47. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26(32): 5204–5212.

48. FDA Statement on Dexrazoxane. Dostupné z WWW: https://www.fda.gov/Drugs/DrugSafety/ucm263729.htm. [7.3.2017].

49. Bosch X, Rovira M, Sitges M et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013; 61(23): 2355–2362.Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.02.072>.

50. Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37(21): 1671–1680. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw022>.

51. Goodman A. Prophylactic Beta-Blocker Preserves Left-Ventricular Function in Patients Receiving Trastuzumab. 2016. Dostupné z WWW: <http://www.ascopost.com/issues/january-25–2016/prophylactic-beta-blocker-preserves-left-ventricular-function-in-patients-receiving-trastuzumab/>.[13.12.2016].

52. Naumann D, Rusius V, Margiotta C et al. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res 2013; 33(4): 1717–1720.

53. Jones AL, Barlow M, Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009; 100(5): 684–692. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.bjc.6604909>.

54. Zamorano LJ, Lancellotti P, Munoz RD et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(36): 2768–2801.

55. Woods T, Vidarsson B, Mosher D et al. Transient effusive-constrictive pericarditis due to chemotherapy. Clin Cardiol 1999; 22(4): 316–318.